Drug Profile
Research programme: antibody therapeutics - AbCheck/Eli Lilly and Company
Latest Information Update: 08 Jan 2024
Price :
$50
*
At a glance
- Originator AbCheck; Eli Lilly and Company
- Class Antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Unspecified